tributyrin has been researched along with Prostatic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altug, V; Genze, F; Gschwend, JE; Hautmann, RE; Hofer, MD; Kuefer, R; Kunzi-Rapp, K; Zorn, C | 1 |
Altug, V; Bachem, M; Gschwend, JE; Hautmann, RE; Maier, S; Martin, R; Reich, E | 1 |
2 other study(ies) available for tributyrin and Prostatic Neoplasms
Article | Year |
---|---|
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
Topics: Administration, Oral; Animals; Apoptosis; Blotting, Western; Butyrates; Disease Models, Animal; Gene Expression Regulation; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Retinoblastoma Protein; Transplantation, Heterologous; Triglycerides; Tumor Cells, Cultured | 2004 |
Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines.
Topics: Androgens; Apoptosis; Butyrates; Cell Cycle; Cell Differentiation; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Prostatic Neoplasms; Triglycerides; Tumor Cells, Cultured | 2000 |